[{"notes_id":"1_1231","category":"11","subcategory":"2","title":"Hormone replacement therapy: adverse effects","body":"Hormone replacement therapy (HRT) involves the use of a small dose of oestrogen (combined with a progestogen in women with a uterus) to help alleviate menopausal symptoms.<br \/><br \/>Side-effects<br \/><ul><li>nausea<\/li><li>breast tenderness<\/li><li>fluid retention and weight gain<\/li><\/ul><br \/>Potential complications<br \/><ul><li>increased risk of breast cancer<ul><li><span class=\"concept\" data-cid=\"239\">increased by the addition of a progestogen<\/span><\/li><li>in the Women's Health Initiative (WHI) study there was a relative risk of 1.26 at 5 years of developing breast cancer<\/li><li>the increased risk relates to the duration of use<\/li><li>the risk of breast cancer begins to decline when HRT is stopped and by 5 years it reaches the same level as in women who have never taken HRT<\/li><\/ul><\/li><li>increased risk of endometrial cancer<ul><li><span class=\"concept\" data-cid=\"238\">oestrogen by itself should not be given as HRT to women with a womb<\/span><\/li><li>reduced by the addition of a progestogen but not eliminated completely<\/li><li>the BNF states that the additional risk is eliminated if a progestogen is given continuously<\/li><\/ul><\/li><li>increased risk of venous thromboembolism<ul><li>increased by the addition of a progestogen<\/li><li><span class=\"concept\" data-cid=\"10891\">transdermal HRT does not appear to increase the risk of VTE<\/span><\/li><li>NICE state women requesting HRT who are at <span class=\"concept\" data-cid=\"10892\">high risk for VTE should be referred to haematology<\/span> before starting any treatment (even transdermal)<\/li><\/ul><\/li><li>increased risk of stroke<\/li><li>increased risk of ischaemic heart disease if taken more than 10 years after menopause<\/li><\/ul>","notes_hash":"232488ce5354f53fe8fb6f211821c566","knowledge_graph_node_id_link":0,"links":"<table style='width:100%'><tr><td>The British Menopause Society and Women's Health Concern<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_434\" data-linkid=\"434\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_434\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">9<\/span><button type=\"button\" style=\"\" id=\"link_dislike_434\" data-linkid=\"434\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_434\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">7<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"http:\/\/journals.sagepub.com\/doi\/abs\/10.1177\/1754045313489645\">Recommendations on hormone replacement therapy<\/a><\/td><\/tr><\/table><br><br><table style='width:100%'><tr><td>NICE<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_332\" data-linkid=\"332\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_332\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">11<\/span><button type=\"button\" style=\"\" id=\"link_dislike_332\" data-linkid=\"332\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_332\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">7<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/www.nice.org.uk\/guidance\/ng23\/chapter\/Recommendations\">2015 Menopause guidelines<\/a><\/td><\/tr><\/table>","media":"","concepts_for_notes":{"238":{"concept_text":"HRT: unopposed oestrogen increases risk of endometrial cancer","concept_percentile":"62"},"239":{"concept_text":"HRT: adding a progestogen increases the risk of breast cancer","concept_percentile":"96"},"10891":{"concept_text":"Transdermal HRT does not appear to increase the risk of VTE (vs. oral) ","concept_percentile":"82"}},"category_name":"Reproductive","subcategory_name":"Gynaecology","comment_count":8},"",[]]